Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EBITDA: 2019-2024

Historic EBITDA for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to -$87.6 million.

  • Mirum Pharmaceuticals' EBITDA rose 120.52% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.8 million, marking a year-over-year increase of 56.45%. This contributed to the annual value of -$87.6 million for FY2024, which is 19.74% up from last year.
  • According to the latest figures from FY2024, Mirum Pharmaceuticals' EBITDA is -$87.6 million, which was up 19.74% from -$109.2 million recorded in FY2023.
  • Mirum Pharmaceuticals' EBITDA's 5-year high stood at -$87.6 million during FY2024, with a 5-year trough of -$173.4 million in FY2021.
  • In the last 3 years, Mirum Pharmaceuticals' EBITDA had a median value of -$109.2 million in 2023 and averaged -$109.3 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' EBITDA slumped by 90.52% in 2020, and later grew by 24.33% in 2022.
  • Mirum Pharmaceuticals' EBITDA (Yearly) stood at -$104.3 million in 2020, then slumped by 66.27% to -$173.4 million in 2021, then climbed by 24.33% to -$131.2 million in 2022, then climbed by 16.82% to -$109.2 million in 2023, then increased by 19.74% to -$87.6 million in 2024.